De Boelelaan 1118
1081 HZ Amsterdam
BiopharmaceuticalsORCA Therapeutics BV is a biopharmaceutical company, based in Amsterdam, The Netherlands, developing a pipeline of innovative anticancer therapies based on the highly promising approach of Oncolytic Replication Competent Agents (ORCA). ORCA Therapeutics’ technology and IP portfolio originates from the research performed at the Department of Medical Oncology at the VU University Medical Center (VUmc) in Amsterdam, the Netherlands. The company has a platform of technologies that are predominantly based on highly engineered oncolytic adenoviruses. ORCA’s lead product ORCA-010 is a new oncolytic adenovirus based on the Company’s proprietary T1 technology. ORCA Therapeutics is currently preparing its ORCA-010 product for testing in prostate cancer patients in a Phase I/II clinical trial.
back to list
ORCA-010, a new oncolytic virus, for treatment of cancer patients.
What we offerORCA Therapeutics B.V. (ORCA) is developing a pipeline of innovative anticancer therapies based on the highly promising approach of oncolytic viruses. ORCA’s value proposition is based on using its proprietary technologies in the field of Oncolytic Replication Competent Agents. ORCA’s lead product ORCA-010 is a new oncolytic adenovirus based on the Company’s proprietary T1 technology. ORCA-010 has up to ten thousand fold higher oncolytic potency as compared to current state of the art oncolytic adenoviruses in a broad panel of cancer cell lines, and has demonstrated strong anticancer activity in various in vivo tumor models. ORCA-010 is currently prepared for a first clinical study in prostate cancer, but can target various other cancer types.
What we are looking forWe are searching investors and/or potential partners to (co-)develop the ORCA-010 product for prostate cancer and potentially other cancer indications.
- Joint Venture Agreement
- Licence Agreement